Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer

Elisabetta Bonzano, Associate Professor at MIUR, shared on X:

“Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.

Both CDK4/6 inhibitors effectively modulate key biological pathways in HR+/HER2‑ breast cancer, nuances in their impact, particularly on the HER2‑enriched signature, are dose‑dependent, influenced by the addition of fulvestrant and warrant further investigation.”

Visit the article website.
Source: Elisabetta Bonzano/X